Tag: Wesana Health - Psychedelic Alpha

Wesana Announces Sale of Clinic Management Services Organization

Post published:September 3, 2022
Post category:Press Release

Wesana Announces Second Quarter 2022 Financial Results

Post published:August 30, 2022
Post category:Press Release

Read more about the article Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Post published:June 8, 2022
Post category:Press Release

Wesana Health Provides Strategic and Operational Updates

Post published:January 12, 2022
Post category:Press Release

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

Post published:January 11, 2022
Post category:Press Release

MAPS and Wesana Health Resume Negotiations

Post published:December 14, 2021
Post category:Press Release

Wesana Health Reports Q3 2021 Financial Results

Post published:November 29, 2021
Post category:Press Release

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

Post published:November 19, 2021
Post category:Press Release

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Post published:September 14, 2021
Post category:Press Release

Wesana Health Announces Closing of PsyTech Acquisition

Post published:September 9, 2021
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Research Review

A monthly review of the most important psychedelics research.

News & Interviews

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Legalization & Decriminalization Tracker

Mapping psychedelic drug policy reform across the United States

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

Wesana Announces Sale of Clinic Management Services Organization

Wesana Announces Second Quarter 2022 Financial Results

Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

Wesana Health Provides Strategic and Operational Updates

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

MAPS and Wesana Health Resume Negotiations

Wesana Health Reports Q3 2021 Financial Results

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline

Wesana Health Announces Closing of PsyTech Acquisition

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.